Skip to main
ALMS

Alumis Inc (ALMS) Stock Forecast & Price Target

Alumis Inc (ALMS) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alumis Inc's innovative approach in developing targeted therapies for autoimmune disorders using its proprietary precision data analytics platform and extensive expertise presents a compelling growth trajectory. The company's differentiated pipeline, particularly the promising outcomes of its TYK2 inhibitor envudeucitinib (envu), positions it favorably against competitors, suggesting a strong potential for long-term efficacy and market leadership within the class. Additionally, positive trends in cost of goods sold (COGS) further enhance the financial outlook, indicating robust operational efficiency as the company advances its development candidates toward commercialization.

Bears say

Alumis Inc faces multiple risks that negatively impact its stock outlook, particularly regarding the advancement and efficacy of its lead candidates ESK-001 and envu in the autoimmune disorders market. The reported efficacy of competitive therapies, coupled with potential delays in regulatory approvals, further complicates the Company's ability to capture significant market share. Additionally, the current enterprise valuation of approximately $730 million does not adequately reflect the heightened challenges regarding market uptake and the possibility of dilution, suggesting financial instability as the Company navigates these hurdles.

Alumis Inc (ALMS) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alumis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alumis Inc (ALMS) Forecast

Analysts have given Alumis Inc (ALMS) a Buy based on their latest research and market trends.

According to 5 analysts, Alumis Inc (ALMS) has a Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alumis Inc (ALMS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.